NYSE · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Lineage Cell Therapeutics, Inc. LCTX
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$14.6M
▲ 53.2% vs FY2024
EPS · FY25
$-0.28
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-103.4%
Net margin · FY25
-436.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 14.6M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 436 cents on every revenue dollar this year.
Per share
USD -0.28
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-103.4%
Return on equity, FY2025
ROE
Operating margin-251.6%
Net margin-436.5%
Return on assets-56.3%
Each USD of equity lost 103 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+51.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−0.3%
+51.5%
+7.5%
+9.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.24B
Shares outstanding, FY2025
Change, 5 years+58.8%
Change, 10 years+168.9%
The share count grew 59% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 112.6M
total assets, end of FY2025
Total assetsUSD 112.6M
EquityUSD 44.5M
CashUSD 40.8M
Current ratio5.20×
Equity funds 40% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
·
·
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
Income tax $B
−0.0
0.0
−0.0
0.0
·
−0.0
−0.0
0.0
·
·
·
·
·
·
·
·
·
Net income $B
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.28
−0.09
−0.12
−0.15
−0.26
−0.14
−0.08
−0.36
−0.17
0.34
−0.59
−0.55
−0.81
−0.44
−0.35
−0.28
−0.18
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−103.4
−26.2
−31.4
−31.7
−45.7
−19.7
−11.3
−35.9
−14.2
46.7
−150.9
−142.1
−359.9
−112.1
−49.4
−29.3
·
Shares out B
0.24
0.22
0.17
0.17
0.17
0.15
0.15
0.13
0.13
0.10
0.09
0.08
0.06
0.05
0.05
0.05
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
62 of 62
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed